Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 196

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 196
---
 of Directors. The Company issues new shares of common stock upon exercise of options. As of December 31, 2024, 3,051,588 shares were available for future grant under the 2021 Plan.

130

A summary of the Company’s stock option activity for the year ended December 31, 2024 was as follows (in thousands, except share and per share data and years): 

        Options

        Weighted-AverageExercisePrice per Share

        Weighted-AverageRemainingContractual Term

        AggregateIntrinsic Value

        Outstanding at December 31, 2023

        8,276,442

        $
        10.07

        8.3

        $
        40,420

        Granted

        3,070,898

        $
        20.60

        Exercised

        (594,990
        )
         
        $
        3.41

        Cancelled

        (290,221
        )
         
        $
        13.93

        Outstanding at December 31, 2024

        10,462,129

        $
        13.43

        7.6

        $
        33,798

        Exercisable at December 31, 2024

        5,042,930

        $
        10.26

        6.4

        $
        26,483

        Vested and expected to vest as of December 31, 2024

        10,462,129

        $
        13.43

        7.6

        $
        33,798

      Employee Stock Purchase PlanIn September 2021, the Company’s Board of Directors adopted, and its stockholders approved, the 2021 Employee Stock Purchase Plan (ESPP). The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. As of December 31, 2024, there were 1,491,195 shares available for future purchase under the ESPP.  The Company recognized compensation expense of